A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of CNTO 1275, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis.

Trial Profile

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of CNTO 1275, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Centocor
  • Most Recent Events

    • 19 Oct 2016 Results of pooled safety analysis from 12 Ustekinumab Crohn's Disease and Psoriatic Diseases trials (n=3636), presented at the 24th United European Gastroenterology Week
    • 13 Jun 2015 Results of pooled analysis of PSUMMIT I, PSUMMIT II and a phase II trial presented at the 16th Annual Congress of the European League Against Rheumatism.
    • 12 Feb 2009 Full article published in Lancet (Online first [8 pages], 12 Feb 2009. Available from: URL: http://www.thelancet.com).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top